<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.journal-inflammation.com/feeds/mostaccessed/journal?quantity=&amp;format=rss&amp;version=">
        <title>Journal of Inflammation - Most accessed articles</title>
        <link>http://www.journal-inflammation.com</link>
        <description>The most accessed research articles published by Journal of Inflammation</description>
        <dc:date>2010-02-19T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.journal-inflammation.com/content/7/1/12" />
                                <rdf:li rdf:resource="http://www.journal-inflammation.com/content/7/1/9" />
                                <rdf:li rdf:resource="http://www.journal-inflammation.com/content/7/1/11" />
                                <rdf:li rdf:resource="http://www.journal-inflammation.com/content/7/1/13" />
                                <rdf:li rdf:resource="http://www.journal-inflammation.com/content/7/1/6" />
                                <rdf:li rdf:resource="http://www.journal-inflammation.com/content/5/1/1" />
                                <rdf:li rdf:resource="http://www.journal-inflammation.com/content/7/1/8" />
                                <rdf:li rdf:resource="http://www.journal-inflammation.com/content/4/1/15" />
                                <rdf:li rdf:resource="http://www.journal-inflammation.com/content/7/1/10" />
                                <rdf:li rdf:resource="http://www.journal-inflammation.com/content/7/1/7" />
                            </rdf:Seq>
        </items>
        <extra:info rdf:parseType="Literal">
            <html:div style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif" xmlns:html="http://www.w3.org/1999/xhtml">
                <html:span style="font-weight:bold">
                    This is an RSS newsfeed from BioMed Central
                </html:span>
                <html:br />
                <html:span style="font-size: 12px;">
                    It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit
                    <html:br />
                    <html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">
                        http://www.biomedcentral.com/info/about/rss/
                    </html:a>
                    <html:br />
                </html:span>
            </html:div>
        </extra:info>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.journal-inflammation.com/content/7/1/12">
        <title>Role of PPAR-delta in the development of zymosan-induced multiple organ failure: an experiment mice study</title>
        <description>Background:
Peroxisome proliferator-activated receptor (PPAR)-beta/delta is a nuclear receptor transcription factor that regulates gene expression in many important biological processes. It is expressed ubiquitously, especially white adipose tissue, heart, muscle, intestine, placenta and macrophages but many of its functions are unknown. Saturated and polyunsaturated fatty acids activate PPAR-beta/delta, but physiological ligands have not yet been identified. In the present study, we investigated the anti-inflammatory effects of PPAR-beta/delta activation, through the use of GW0742 (0,3 mg/kg 10 % Dimethyl sulfoxide (DMSO) i.p), a synthetic high affinity ligand, on the development of zymosan-induced multiple organ failure (MOF).
Methods:
Multiple organ failure (MOF) was induced in mice by administration of zymosan (given at 500 mg/kg, i.p. as a suspension in saline). The control groups were treated with vehicle (0.25 ml/mouse saline), while the pharmacological treatment was the administration of GW0742 (0,3 mg/kg 10 % DMSO i.p. 1h and 6h after zymosan administration). MOF and systemic inflammation in mice was assessed 18 hours after administration of zymosan.
Results:
Treatment with GW0742 caused a significant reduction of the peritoneal exudate formation and of the neutrophil infiltration caused by zymosan resulting in a reduction in myeloperoxidase activity. The PPAR-beta/delta agonist, GW0742, at the dose of 0,3 mg/kg in 10 % DMSO, also attenuated the multiple organ dysfunction syndrome caused by zymosan. In pancreas, lung and gut, immunohistochemical analysis of some end points of the inflammatory response, such as inducible nitric oxide synthase (iNOS), nitrotyrosine, poly (ADP-ribose) (PAR), TNF- and IL-1as well as FasL, Bax, Bcl-2 and apoptosis, revealed positive staining in sections of tissue obtained from zymosan-injected mice. On the contrary, these parameters were markedly reduced in samples obtained from mice treated with GW0742
Conclusions:
In this study, we have shown that GW0742 attenuates the degree of zymosan-induced non-septic shock in mice.</description>
        <link>http://www.journal-inflammation.com/content/7/1/12</link>
                <dc:creator>Maria Galuppo</dc:creator>
                <dc:creator>Rosanna di Paola</dc:creator>
                <dc:creator>Emanuela Mazzon</dc:creator>
                <dc:creator>Tiziana Genovese</dc:creator>
                <dc:creator>Concetta Crisafulli</dc:creator>
                <dc:creator>Irene Paterniti</dc:creator>
                <dc:creator>Elisabetta Cuzzocrea</dc:creator>
                <dc:creator>Placido Bramanti</dc:creator>
                <dc:creator>Amar Kapoor</dc:creator>
                <dc:creator>Christoph Thiemermann</dc:creator>
                <dc:creator>Salvatore Cuzzocrea</dc:creator>
                <dc:source>Journal of Inflammation 2010, 7:12</dc:source>
        <dc:date>2010-02-18T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-9255-7-12</dc:identifier>
        <prism:publicationName>Journal of Inflammation</prism:publicationName>
        <prism:issn>1476-9255</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>12</prism:startingPage>
        <prism:publicationDate>2010-02-18T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.journal-inflammation.com/content/7/1/9">
        <title>Histone deacetylase inhibitors induce apoptosis in human eosinophils and neutrophils</title>
        <description>Background:
Granulocytes are important in the pathogenesis of several inflammatory diseases. Apoptosis is pivotal in the resolution of inflammation. Apoptosis in malignant cells is induced by histone deacetylase (HDAC) inhibitors, whereas HDAC inhibitors do not usually induce apoptosis in non-malignant cells. The aim of the present study was to explore the effects of HDAC inhibitors on apoptosis in human eosinophils and neutrophils.
Methods:
Apoptosis was assessed by relative DNA fragmentation assay, annexin-V binding, and morphologic analysis. HDAC activity in nuclear extracts was measured with a nonisotopic assay. HDAC expression was measured by real-time PCR.
Results:
A HDAC inhibitor Trichostatin A (TSA) induced apoptosis in the presence of survival-prolonging cytokines interleukin-5 and granulocyte-macrophage colony stimulating factor (GM-CSF) in eosinophils and neutrophils. TSA enhanced constitutive eosinophil and neutrophil apoptosis. Similar effects were seen with a structurally dissimilar HDAC inhibitor apicidin. TSA showed additive effect on the glucocorticoid-induced eosinophil apoptosis, but antagonized glucocorticoid-induced neutrophil survival. Eosinophils and neutrophils expressed all HDACs at the mRNA level except that HDAC5 and HDAC11 mRNA expression was very low in both cell types, HDAC8 mRNA was very low in neutrophils and HDAC9 mRNA low in eosinophils. TSA reduced eosinophil and neutrophil nuclear HDAC activities by ~50-60%, suggesting a non-histone target. However, TSA did not increase the acetylation of a non-histone target NF-kB p65. c-jun-N-terminal kinase and caspases 3 and 6 may be involved in the mechanism of TSA-induced apoptosis, whereas PI3-kinase and caspase 8 are not.
Conclusions:
HDAC inhibitors enhance apoptosis in human eosinophils and neutrophils in the absence and presence of survival-prolonging cytokines and glucocorticoids.</description>
        <link>http://www.journal-inflammation.com/content/7/1/9</link>
                <dc:creator>Hannu Kankaanranta</dc:creator>
                <dc:creator>Mirkka Janka-Junttila</dc:creator>
                <dc:creator>Pinja Ilmarinen-Salo</dc:creator>
                <dc:creator>Kazuhiro Ito</dc:creator>
                <dc:creator>Ulla Jalonen</dc:creator>
                <dc:creator>Misako Ito</dc:creator>
                <dc:creator>Ian Adcock</dc:creator>
                <dc:creator>Eeva Moilanen</dc:creator>
                <dc:creator>Xianzhi Zhang</dc:creator>
                <dc:source>Journal of Inflammation 2010, 7:9</dc:source>
        <dc:date>2010-02-04T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-9255-7-9</dc:identifier>
        <prism:publicationName>Journal of Inflammation</prism:publicationName>
        <prism:issn>1476-9255</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>9</prism:startingPage>
        <prism:publicationDate>2010-02-04T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.journal-inflammation.com/content/7/1/11">
        <title>Cigarette smoke regulates VEGFR2-mediated survival signaling in rat lungs</title>
        <description>Background:
Vascular endothelial growth factor (VEGF) and VEGF receptor 2 (VEGFR2)-mediated survival signaling is critical to endothelial cell survival, maintenance of the vasculature and alveolar structure and regeneration of lung tissue. Reduced VEGF and VEGFR2 expression in emphysematous lungs has been linked to increased endothelial cell death and vascular regression. Previously, we have shown that CS down-regulated the VEGFR2 and its downstream signaling in mouse lungs. However, the VEGFR2-mediated survival signaling in response to oxidants/cigarette smoke (CS) is not known. We hypothesized that CS exposure leads to disruption of VEGFR2-mediated endothelial survival signaling in rat lungs.
Methods:
Adult male Sprague-Dawley rats were exposed CS for 3 days, 8 weeks and 6 months to investigate the effect of CS on VEGFR2-mediated survival signaling by measuring the Akt/PI3-kinase/eNOS downstream signaling in rat lungs.Results and DiscussionWe show that CS disrupts VEGFR2/PI3-kinase association leading to decreased Akt and eNOS phosphorylation. This may further alter the phosphorylation of the pro-apoptotic protein Bad and increase the Bad/Bcl-xl association. However, this was not associated with a significant lung cell death as evidenced by active caspase-3 levels. These data suggest that although CS altered the VEGFR2-mediated survival signaling in the rat lungs, but it was not sufficient to cause lung cell death.
Conclusion:
The rat lungs exposed to CS in acute, sub-chronic and chronic levels may be representative of smokers where survival signaling is altered but was not associated with lung cell death whereas emphysema is known to be associated with lung cell apoptosis.</description>
        <link>http://www.journal-inflammation.com/content/7/1/11</link>
                <dc:creator>John Marwick</dc:creator>
                <dc:creator>Indika Edirisinghe</dc:creator>
                <dc:creator>Gnanapragasam Arunachalam</dc:creator>
                <dc:creator>Christopher Stevenson</dc:creator>
                <dc:creator>William MacNee</dc:creator>
                <dc:creator>Paul Kirkham</dc:creator>
                <dc:creator>Irfan Rahman</dc:creator>
                <dc:source>Journal of Inflammation 2010, 7:11</dc:source>
        <dc:date>2010-02-13T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-9255-7-11</dc:identifier>
        <prism:publicationName>Journal of Inflammation</prism:publicationName>
        <prism:issn>1476-9255</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>11</prism:startingPage>
        <prism:publicationDate>2010-02-13T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.journal-inflammation.com/content/7/1/13">
        <title>Anti-inflammatory activity of nanocrystalline silver-derived solutions in porcine contact dermatitis</title>
        <description>Background:
Nanocrystalline silver dressings have anti-inflammatory activity, unlike solutions containing Ag+ only, which may be due to dissolution of multiple silver species.  These dressings can only be used to treat surfaces.  Thus, silver-containing solutions with nanocrystalline silver properties could be valuable for treating hard-to-dress surfaces and inflammatory conditions of the lungs and bowels.  This study tested nanocrystalline silver-derived solutions for anti-inflammatory activity.
Methods:
Inflammation was induced on porcine backs using dinitrochlorobenzene.  Negative and positive controls were treated with distilled water.  Experimental groups were treated with solutions generated by dissolving nanocrystalline silver in distilled water adjusted to starting pHs of 4 (using CO2), 5.6 (as is), 7, and 9 (using Ca(OH)2).  Solution samples were analyzed for total silver.  Daily imaging, biopsying, erythema and oedema scoring, and treatments were performed for three days.  Biopsies were processed for histology, immunohistochemistry (for IL-4, IL-8, IL-10, TNF-alpha, EGF, KGF, KGF-2, and apoptotic cells), and zymography (MMP-2 and -9).  One-way ANOVAs with Tukey-Kramer post tests were used for statistical analyses.
Results:
Animals treated with pH 7 and 9 solutions showed clear visual improvements.  pH 9 solutions resulted in the most significant reductions in erythema and oedema scores.  pH 4 and 7 solutions also reduced oedema scores.  Histologically, all treatment groups demonstrated enhanced re-epithelialisation, with decreased inflammation.  At 24h, pMMP-2 expression was significantly lowered with pH 5.6 and 9 treatments, as was aMMP-2 expression with pH 9 treatments.  In general, treatment with silver-containing solutions resulted in decreased TNF-alpha and IL-8 expression, with increased IL-4, EGF, KGF, and KGF-2 expression.  At 24h, apoptotic cells were detected mostly in the dermis with pH 4 and 9 treatments, nowhere with pH 5.6, and in both the epidermis and dermis with pH 7.  Solution anti-inflammatory activity did not correlate with total silver content, as pH 4 solutions contained significantly more silver than all others.
Conclusions:
Nanocrystalline silver-derived solutions appear to have anti-inflammatory/pro-healing activity, particularly with a starting pH of 9.  Solutions generated differently may have varying concentrations of different silver species, only some of which are anti-inflammatory.  Nanocrystalline silver-derived solutions show promise for a variety of anti-inflammatory treatment applications.</description>
        <link>http://www.journal-inflammation.com/content/7/1/13</link>
                <dc:creator>Patricia Nadworny</dc:creator>
                <dc:creator>JianFei Wang</dc:creator>
                <dc:creator>Edward Tredget</dc:creator>
                <dc:creator>Robert Burrell</dc:creator>
                <dc:source>Journal of Inflammation 2010, 7:13</dc:source>
        <dc:date>2010-02-19T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-9255-7-13</dc:identifier>
        <prism:publicationName>Journal of Inflammation</prism:publicationName>
        <prism:issn>1476-9255</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>13</prism:startingPage>
        <prism:publicationDate>2010-02-19T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.journal-inflammation.com/content/7/1/6">
        <title>Early lactate clearance is associated with biomarkers of inflammation, coagulation, apoptosis, organ dysfunction and mortality in severe sepsis and septic shock</title>
        <description>Background:
Lactate clearance, a surrogate for the magnitude and duration of global tissue hypoxia, is used diagnostically, therapeutically and prognostically. This study examined the association of early lactate clearance with selected inflammatory, coagulation, apoptosis response biomarkers and organ dysfunction scores in severe sepsis and septic shock.
Methods:
Measurements of serum arterial lactate, biomarkers (interleukin-1 receptor antagonist, interleukin-6, interleukin-8, interleukin-10, tumor necrosis factor-alpha, intercellular adhesion molecule-1, high mobility group box-1, D-Dimer and caspase-3), and organ dysfunction scores (Acute Physiology and Chronic Health Evaluation II, Simplified Acute Physiology Score II, Multiple Organ Dysfunction Score, and Sequential Organ Failure Assessment) were obtained in conjunction with a prospective, randomized study examining early goal-directed therapy in severe sepsis and septic shock patients presenting to the emergency department (ED). Lactate clearance was defined as the percent change in lactate levels after six hours from a baseline measurement in the ED.
Results:
Two-hundred and twenty patients, age 65.0 +/- 17.1 years, were examined, with an overall lactate clearance of 35.5 +/- 43.1% and in-hospital mortality rate of 35.0%. Patients were divided into four quartiles of lactate clearance, -24.3 +/- 42.3, 30.1 +/- 7.5, 53.4 +/- 6.6, and 75.1 +/- 7.1%, respectively (p &lt; 0.01). The mean levels of all biomarkers and organ dysfunction scores over 72 hours were significantly lower with higher lactate clearance quartiles (p &lt; 0.01). There was a significant decreased in-hospital, 28-day, and 60-day mortality in the higher lactate clearance quartiles (p &lt; 0.01).
Conclusions:
Early lactate clearance as a surrogate for the resolution of global tissue hypoxia is significantly associated with decreased levels of biomarkers, improvement in organ dysfunction and outcome in severe sepsis and septic shock.</description>
        <link>http://www.journal-inflammation.com/content/7/1/6</link>
                <dc:creator>H. Bryant Nguyen</dc:creator>
                <dc:creator>Manisha Loomba</dc:creator>
                <dc:creator>James Yang</dc:creator>
                <dc:creator>Gordon Jacobsen</dc:creator>
                <dc:creator>Kant Shah</dc:creator>
                <dc:creator>Ronny Otero</dc:creator>
                <dc:creator>Arturo Suarez</dc:creator>
                <dc:creator>Hemal Parekh</dc:creator>
                <dc:creator>Anja Jaehne</dc:creator>
                <dc:creator>Emanuel Rivers</dc:creator>
                <dc:source>Journal of Inflammation 2010, 7:6</dc:source>
        <dc:date>2010-01-28T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-9255-7-6</dc:identifier>
        <prism:publicationName>Journal of Inflammation</prism:publicationName>
        <prism:issn>1476-9255</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>6</prism:startingPage>
        <prism:publicationDate>2010-01-28T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.journal-inflammation.com/content/5/1/1">
        <title>Topical anti-inflammatory activity of Polygonum cuspidatum extract in the TPA model of mouse ear inflammation</title>
        <description>Background:
This study tested the ability of a characterized extract of Polygonum cuspidatum (PCE) to inhibit mouse ear inflammation in response to topical application of 12-O-tetradecanoylphorbol-13-acetate (TPA).
Methods:
A 50% (wt:vol) ethanolic solution of commercial 200:1 PCE was applied to both ears of female Swiss mice (n = 8) at 0.075, 0.15, 0.3, 1.25 and 2.5 mg/ear 30 min after TPA administration (2 &#956;g/ear). For comparison, 3 other groups were treated with TPA and either 1) the vehicle (50% ethanol) alone, 2) indomethacin (0.5 mg/ear), or 3) trans-resveratrol (0.62 mg/ear). Ear thickness was measured before TPA and at 4 and 24 h post-TPA administration to assess ear edema. Ear punch biopsies were collected at 24 h and weighed as a second index of edema. Myeloperoxidase activity was measured in each ear punch biopsy to assess neutrophil infiltration.
Results:
PCE treatment at all doses significantly reduced ear edema compared to the TPA control. The PCE response was dose-dependent and 2.5 mg PCE significantly inhibited all markers of inflammation to a greater extent than indomethacin (0.5 mg). MPO activity was inhibited at PCE doses &#8805; 1.25 mg/ear. Trans-resveratrol inhibited inflammation at comparable doses.
Conclusion:
PCE inhibits development of edema and neutrophil infiltration in the TPA-treated mouse ear model of topical inflammation.</description>
        <link>http://www.journal-inflammation.com/content/5/1/1</link>
                <dc:creator>Eve Bralley</dc:creator>
                <dc:creator>Phillip Greenspan</dc:creator>
                <dc:creator>James Hargrove</dc:creator>
                <dc:creator>Louise Wicker</dc:creator>
                <dc:creator>Diane Hartle</dc:creator>
                <dc:source>Journal of Inflammation 2008, 5:1</dc:source>
        <dc:date>2008-02-08T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-9255-5-1</dc:identifier>
        <prism:publicationName>Journal of Inflammation</prism:publicationName>
        <prism:issn>1476-9255</prism:issn>
        <prism:volume>5</prism:volume>
        <prism:startingPage>1</prism:startingPage>
        <prism:publicationDate>2008-02-08T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.journal-inflammation.com/content/7/1/8">
        <title>Suppression of LPS-induced inflammatory responses in macrophages infected with Leishmania </title>
        <description>Background:
Chronic inflammation activated by macrophage innate pathogen recognition receptors such as TLR4 can lead to a range of inflammatory diseases, including atherosclerosis, Crohn&apos;s disease, arthritis and cancer. Unlike many microbes, the kinetoplastid protozoan pathogen Leishmania has been shown to avoid and even actively suppress host inflammatory cytokine responses, such as LPS-induced IL-12 production. The nature and scope of Leishmania-mediated inflammatory cytokine suppression, however, is not well characterized. Advancing our knowledge of such microbe-mediated cytokine suppression may provide new avenues for therapeutic intervention in inflammatory disease.
Methods:
We explored the kinetics of a range of cytokine and chemokine responses in primary murine macrophages stimulated with LPS in the presence versus absence of two clinically distinct species of Leishmania using sensitive multiplex cytokine analyses. To confirm that these effects were parasite-specific, we compared the effects of Leishmania uptake on LPS-induced cytokine expression with uptake of inert latex beads.
Results:
Whilst Leishmania uptake alone did not induce significant levels of any cytokine analysed in this study, Leishmania uptake in the presence of LPS caused parasite-specific suppression of certain LPS-induced pro-inflammatory cytokines, including IL-12, IL-17 and IL-6. Interestingly, L. amazonensis was generally more suppressive than L. major. We also found that other LPS-induced proinflammatory cytokines, such as IL-1&#945;, TNF-&#945; and the chemokines MIP-1&#945; and MCP-1 and also the anti-inflammatory cytokine IL-10, were augmented during Leishmania uptake, in a parasite-specific manner.
Conclusions:
During uptake by macrophages, Leishmania evades the activation of a broad range of cytokines and chemokines. Further, in the presence of a strong inflammatory stimulus, Leishmania suppresses certain proinflammatory cytokine responses in a parasite-specific manner, however it augments the production of other proinflammatory cytokines. Our findings highlight the complexity of inflammatory cytokine signalling regulation in the context of the macrophage and Leishmania interaction and confirm the utility of the Leishmania/macrophage infection model as an experimental system for further studies of inflammatory regulation. Such studies may advance the development of therapies against inflammatory disease.</description>
        <link>http://www.journal-inflammation.com/content/7/1/8</link>
                <dc:creator>Nicholas Lapara</dc:creator>
                <dc:creator>Ben Kelly</dc:creator>
                <dc:source>Journal of Inflammation 2010, 7:8</dc:source>
        <dc:date>2010-02-02T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-9255-7-8</dc:identifier>
        <prism:publicationName>Journal of Inflammation</prism:publicationName>
        <prism:issn>1476-9255</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>8</prism:startingPage>
        <prism:publicationDate>2010-02-02T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.journal-inflammation.com/content/4/1/15">
        <title>Free radical scavenging activity and lipoxygenase inhibition of Mahonia aquifolium extract and isoquinoline alkaloids</title>
        <description>Roots and stem-bark of Mahonia aquifolium (Oregon grape) (Berberidaceae) are effectively used in the treatment of skin inflammatory conditions.In the present study, the effect of Mahonia aquifolium crude extract and its two representative alkaloid fractions containing protoberberine and bisbenzylisoquinoline (BBIQ) alkaloids on activity of 12-lipoxygenase (12-LOX), was studied. The reactivity with 1,1-diphenyl-2-picryl-hydrazyl (DPPH), a free stable radical, was evaluated to elucidate the rate of possible lipid-derived radical scavenging in the mechanism of the enzyme inhibition.The results indicate that although the direct radical scavenging mechanism cannot be ruled out in the lipoxygenase inhibition by Mahonia aquifolium and its constituents, other mechanisms based on specific interaction between enzyme and alkaloids could play the critical role in the lipoxygenase inhibition rather than non-specific reactivity with free radicals.</description>
        <link>http://www.journal-inflammation.com/content/4/1/15</link>
                <dc:creator>Lucia Rackova</dc:creator>
                <dc:creator>Marek Oblozinsky</dc:creator>
                <dc:creator>Daniela Kostalova</dc:creator>
                <dc:creator>Viktor Kettmann</dc:creator>
                <dc:creator>Lydia Bezakova</dc:creator>
                <dc:source>Journal of Inflammation 2007, 4:15</dc:source>
        <dc:date>2007-07-16T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-9255-4-15</dc:identifier>
        <prism:publicationName>Journal of Inflammation</prism:publicationName>
        <prism:issn>1476-9255</prism:issn>
        <prism:volume>4</prism:volume>
        <prism:startingPage>15</prism:startingPage>
        <prism:publicationDate>2007-07-16T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.journal-inflammation.com/content/7/1/10">
        <title>CD73 represses pro-inflammatory responses in human endothelial cells</title>
        <description>Background:
CD73 is a 5&apos;-ectonucleotidase that produces extracellular adenosine, which then acts on G protein-coupled purigenic receptors to induce cellular responses. CD73 has been reported to regulate expression of pro-inflammatory molecules in mouse endothelium. Our aim is to determine the function of CD73 in human endothelial cells.
Methods:
We used RNAi to deplete CD73 levels in human umbilical cord endothelial cells (HUVECs).
Results:
CD73 depletion resulted in a strong reduction in adenosine production, indicating that CD73 is the major source of extracellular adenosine in HUVECs. We find that CD73 depletion induces a similar response to pro-inflammatory stimuli such as the cytokine TNF-&#945;. In CD73-depleted cells, surface levels of the leukocyte adhesion molecules ICAM-1, VCAM-1 and E-selectin increase. This correlates with increased translocation of the transcription factor NF-kB to the nucleus, which is known to regulate ICAM-1, VCAM-1 and E-selectin expression in response to TNF-&#945;. Adhesion of monocytic cells to endothelial cells is enhanced. In addition, CD73-depleted cells become elongated, have higher levels of stress fibres and increased endothelial permeability, resembling known responses to TNF-&#945;.
Conclusions:
These results indicate that CD73 normally suppresses pro-inflammatory responses in human endothelial cells.</description>
        <link>http://www.journal-inflammation.com/content/7/1/10</link>
                <dc:creator>Jana Gruenewald</dc:creator>
                <dc:creator>Anne Ridley</dc:creator>
                <dc:source>Journal of Inflammation 2010, 7:10</dc:source>
        <dc:date>2010-02-05T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-9255-7-10</dc:identifier>
        <prism:publicationName>Journal of Inflammation</prism:publicationName>
        <prism:issn>1476-9255</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>10</prism:startingPage>
        <prism:publicationDate>2010-02-05T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.journal-inflammation.com/content/7/1/7">
        <title>Dextran sulfate sodium and 2,4,6-trinitrobenzene sulfonic acid induce lipid peroxidation by the proliferation of intestinal gram-negative bacteria in mice</title>
        <description>Abstrect
Background:
To understand whether TLR-4-linked NF-kB activation negatively correlates with lipid peroxidation in colitic animal models, we caused colitis by the treatment with dextran sulfate sodium (DSS) or 2,4,6-trinitrobenzenesulfonic acid (TNBS) to C3H/HeJ (TLR-4-defective) and C3H/HeN (wild type) mice, investigated inflammatory markers, lipid peroxidation, proinflammatory cytokines and TLR-4-linked NF-&#954;B activation, in colon and intestinal bacterial composition in vivo.
Methods:
Orally administered DSS and intrarectally injected TNBS all caused severe inflammation, manifested by shortened colons in both mice. These agents increased intestinal myeloperoxidase activity and the expression of the proinflammatory cytokines, IL-1&#946;, TNF-&#945; and IL-6, in the colon.
Results:
DSS and TNBS induced the protein expression of TLR-4 and activated transcription factor NF-&#954;B. However, these colitic agents did not express TLR-4 in C3H/HeJ mice. Of proinflammatory cytokines, IL-1&#946; was most potently expressed in C3H/HeN mice. IL-1&#946; potently induced NF-&#954;B activation in CaCo-2 cells, but did not induce TLR-4 expression. DSS and TNBS increased lipid peroxide (malondialdehyde) and 4-hydroxy-2-nonenal content in the colon, but reduced glutathione content and superoxide dismutase and catalase activities. These colitic inducers increased the number of Enterobacteriaceae grown in DHL agar plates in both mice, although the number of anaerobes and bifidobacteria grown in GAM and BL agar plates was reduced. E. coli, K. pneumoniae and Proteus mirabilis isolated in DHL agar plates increased lipid peroxidation in liposomes prepared by L-&#945;-phosphatidylcholine, but B. animalis and B. cholerium isolated from BL agar plates inhibited it.DiscussionThese findings suggest that DSS and TNBS may cause colitis by inducing lipid peroxidation and enterobacterial proliferation, which may deteriorate the colitis by regulating proinflammatory cytokines via TLR-4-linked NF-&#954;B activation pathway.</description>
        <link>http://www.journal-inflammation.com/content/7/1/7</link>
                <dc:creator>In-Ah Lee</dc:creator>
                <dc:creator>Eun-Ah Bae</dc:creator>
                <dc:creator>Yang-Jin Hyun</dc:creator>
                <dc:creator>Dong-Hyun Kim</dc:creator>
                <dc:source>Journal of Inflammation 2010, 7:7</dc:source>
        <dc:date>2010-02-01T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-9255-7-7</dc:identifier>
        <prism:publicationName>Journal of Inflammation</prism:publicationName>
        <prism:issn>1476-9255</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>7</prism:startingPage>
        <prism:publicationDate>2010-02-01T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
